Caribou Biosciences (CRBU) EBITDA (2020 - 2026)
Caribou Biosciences (CRBU) reported EBITDA of -$25.2 million for Q1 2026, up 37.1% year-over-year from -$18.4 million in Q1 2025, and up 4.79% quarter-over-quarter from -$26.5 million in Q4 2025.
Caribou Biosciences (CRBU) EBITDA (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of EBITDA data on file, last reported at -$25.2 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$25.2 million, up 37.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$133.4 million (up 9.48% YoY), and the FY2025 annual result was -$148.3 million, changed 0.41% from the prior year.
- EBITDA grew to -$25.2 million in Q1 2026 per CRBU's latest filing, from -$26.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$9.8 million in Q3 2023 and troughed at -$54.2 million in Q2 2025.
- A 5-year average of -$30.8 million and a median of -$27.5 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA surged 63.67% in 2023, then plunged 240.98% in 2024.
- A 5-year view of EBITDA shows it stood at -$26.5 million in 2022, then dropped by 26.53% to -$33.5 million in 2023, then fell by 7.55% to -$36.0 million in 2024, then advanced by 26.5% to -$26.5 million in 2025, then climbed by 4.79% to -$25.2 million in 2026.
- Business Quant data shows CRBU's EBITDA at -$25.2 million in Q1 2026, -$26.5 million in Q4 2025, and -$27.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | -25.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.21 Mn |
| Dec 31, 2025 | -26.48 Mn |
| Sep 30, 2025 | -27.50 Mn |
| Jun 30, 2025 | -54.23 Mn |
| Mar 31, 2025 | -40.08 Mn |
| Dec 31, 2024 | -36.02 Mn |
| Sep 30, 2024 | -33.58 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -41.59 Mn |
| Dec 31, 2023 | -33.49 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -29.93 Mn |
| Mar 31, 2023 | -27.26 Mn |
| Dec 31, 2022 | -26.47 Mn |
| Sep 30, 2022 | -27.10 Mn |
| Jun 30, 2022 | -27.19 Mn |
| Mar 31, 2022 | -20.04 Mn |
| Dec 31, 2021 | -18.61 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -14.31 Mn |